Hear from IMS’s Mandy Chui about China and why many of the big names in pharma are ill-prepared for the opportunities ahead; how conventional sales models no longer apply and which strategies may hold a key to a new world of success.
The document outlines the objectives, population, considerations, and process for the ACS Snapshot Survey/Registry study. The main objectives are to assess management and outcomes of AMI patients across European countries and regions in real-world practice settings. The study will enroll 3000-5000 consecutive AMI patients admitted to ICUs in Europe over a one-week period in December 2009. Participating sites will enter patient data into an online case report form to analyze management patterns and in-hospital outcomes.
Business opportunities in private hospital sector in indiaBusiness Finland
The document summarizes business opportunities in India's private hospital sector. It notes that the healthcare industry in India is growing rapidly at 20% annually and is expected to reach $100 billion by 2015. The private sector accounts for 65% of hospital beds and 80% of healthcare spending, and is growing at 24.1% annually. Opportunities exist for foreign companies in areas like medical equipment, diagnostic devices, health IT, and green building technologies. The largest private hospital chains in India are outlined. Fast growing specialty areas include oncology, orthopedics, and cardiology.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
The document discusses the history and context around why the United States does not have universal healthcare. It traces the evolution of the healthcare system from the early 1900s through various reforms. While many argue universal healthcare could help prevent deaths and bankruptcy, others believe it would burden taxpayers as it is not free. Historically, the US healthcare system has undergone shifts between private and public involvement through reforms. Legislatively, the checks and balances system and power of private sectors have made it difficult for universal healthcare legislation to pass due to concerns over costs and government control of the economy.
1) The introduction of smartphones in China has propelled its healthcare industry into new areas, but mHealth has not yet dominated due to issues like unmet doctor needs, poor medical coverage, and lack of trust in reliability.
2) A successful example is Sanofi's diabetes mHealth program providing rural residents access to medical experts, and helping companies understand patient needs.
3) Customizing doctor information on platforms like "Ding Xiang Yuan" and "Chunyu Yisheng" allows companies to deliver individualized options to gain insight into doctor needs in the market.
- The document compares the personalities and business strategies of the CEOs of Merck KGaA and Merck & Co.
- Merck KGaA's CEO Karl-Ludwig Kley emphasizes profit maximization and acquisitions to sustain long-term growth, while Merck & Co.'s CEO Kenneth Frazier prioritizes research and development to bring new medicines to patients.
- Despite differing approaches, both companies are now investing heavily in biopharmaceuticals to benefit healthcare systems and patients worldwide.
Amid a general slowdown of the global pharmaceutical market, pharmerging markets continue to be a formidable engine of growth; across Asia, Africa and South America, these markets are boasting a CAGR of 10-14%. At the outer edges of these growing economies are markets identified by IMS Health as “Frontier Markets” – the next big drivers of growth, opportunity and even innovation.
Among the Frontier Markets, Myanmar is capturing the most attention. With the completion of parliamentary elections in early November of 2015, there are positive signs that the momentum for change and market liberalization will accelerate. Indeed, Myanmar resembles the early days of some of today’s leading Asian developing markets such as Vietnam and Indonesia. However, while understanding the similarities is certainly valuable, the temptation to merely duplicate entry strategies and market assumptions should be resisted. Myanmar’s underinvested healthcare infrastructure, sizeable talent gaps, and significant regulatory and affordability hurdles, require an informed approach, and managed expectations. Multinationals will be challenged to re-evaluate what it takes to play, and what it means to win in both the short and long term.
The document outlines the objectives, population, considerations, and process for the ACS Snapshot Survey/Registry study. The main objectives are to assess management and outcomes of AMI patients across European countries and regions in real-world practice settings. The study will enroll 3000-5000 consecutive AMI patients admitted to ICUs in Europe over a one-week period in December 2009. Participating sites will enter patient data into an online case report form to analyze management patterns and in-hospital outcomes.
Business opportunities in private hospital sector in indiaBusiness Finland
The document summarizes business opportunities in India's private hospital sector. It notes that the healthcare industry in India is growing rapidly at 20% annually and is expected to reach $100 billion by 2015. The private sector accounts for 65% of hospital beds and 80% of healthcare spending, and is growing at 24.1% annually. Opportunities exist for foreign companies in areas like medical equipment, diagnostic devices, health IT, and green building technologies. The largest private hospital chains in India are outlined. Fast growing specialty areas include oncology, orthopedics, and cardiology.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
The document discusses the history and context around why the United States does not have universal healthcare. It traces the evolution of the healthcare system from the early 1900s through various reforms. While many argue universal healthcare could help prevent deaths and bankruptcy, others believe it would burden taxpayers as it is not free. Historically, the US healthcare system has undergone shifts between private and public involvement through reforms. Legislatively, the checks and balances system and power of private sectors have made it difficult for universal healthcare legislation to pass due to concerns over costs and government control of the economy.
1) The introduction of smartphones in China has propelled its healthcare industry into new areas, but mHealth has not yet dominated due to issues like unmet doctor needs, poor medical coverage, and lack of trust in reliability.
2) A successful example is Sanofi's diabetes mHealth program providing rural residents access to medical experts, and helping companies understand patient needs.
3) Customizing doctor information on platforms like "Ding Xiang Yuan" and "Chunyu Yisheng" allows companies to deliver individualized options to gain insight into doctor needs in the market.
- The document compares the personalities and business strategies of the CEOs of Merck KGaA and Merck & Co.
- Merck KGaA's CEO Karl-Ludwig Kley emphasizes profit maximization and acquisitions to sustain long-term growth, while Merck & Co.'s CEO Kenneth Frazier prioritizes research and development to bring new medicines to patients.
- Despite differing approaches, both companies are now investing heavily in biopharmaceuticals to benefit healthcare systems and patients worldwide.
Amid a general slowdown of the global pharmaceutical market, pharmerging markets continue to be a formidable engine of growth; across Asia, Africa and South America, these markets are boasting a CAGR of 10-14%. At the outer edges of these growing economies are markets identified by IMS Health as “Frontier Markets” – the next big drivers of growth, opportunity and even innovation.
Among the Frontier Markets, Myanmar is capturing the most attention. With the completion of parliamentary elections in early November of 2015, there are positive signs that the momentum for change and market liberalization will accelerate. Indeed, Myanmar resembles the early days of some of today’s leading Asian developing markets such as Vietnam and Indonesia. However, while understanding the similarities is certainly valuable, the temptation to merely duplicate entry strategies and market assumptions should be resisted. Myanmar’s underinvested healthcare infrastructure, sizeable talent gaps, and significant regulatory and affordability hurdles, require an informed approach, and managed expectations. Multinationals will be challenged to re-evaluate what it takes to play, and what it means to win in both the short and long term.
The insights driving superior healthcare outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region, delivering fresh perspectives on how to navigate through the challenges and opportunities in Asia-Pacific pharmaceutical market.
1. The document discusses opportunities for France and China to collaborate on improving China's healthcare system to address the country's changing demographic and economic landscape.
2. It outlines four priority areas: developing more patient-centric hospitals and health information systems, caring for an aging population, preventing and managing chronic diseases, and fighting infectious diseases.
3. France is well-positioned to offer relevant experiences and innovative solutions in these areas through its healthcare expertise, long-standing relationship with China, and companies working in areas like hospital design, elderly care, disease prevention and treatment.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
The document provides insights into OTC market trends in the APAC region. It finds that growth in APAC comes from both innovation in new products and base sales growth, while the global market still relies heavily on price increases. Among key categories in APAC, pain relief is driving growth above the regional average, while categories like cough/cold struggle. The report also notes that just 4 of the top 10 OTC corporations in APAC are multinational companies, and only Takeda grows faster than the overall APAC market.
This document summarizes key trends in real-world evidence (RWE) research, with a focus on diabetes. It discusses how new mixed methods and analytic innovations are providing deeper insights into differential treatment responses in diabetes patient subgroups. It also describes emerging RWE strategies like disease-centric frameworks and increased commercial collaboration. Finally, it highlights advances in predictive modeling, leveraging Scandinavian data sources, and using RWE to evaluate disease burden and non-adherence impacts.
The insights driving superior healthcare
outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region to engage in conversations about the forces that are shaping healthcare in Asia - and the strategies necessary to surge ahead of the competition
Growing Pains. China new's realities and the necessity of an informed strateg...QuintilesIMS Asia Pacific
China is a rapidly evolving healthcare market. However companies that take too macroscopic approach to projecting growth, disregarding the more granular trends across drug categories, risk facing a gap between assumed and actual portfolio growth. To address this gap, companies have a variety of options, ranging across levels of difficulty and the degree of transformation necessary.
Download the paper to learn more.
To succeed in this dynamic healthcare industry, price-volume strategies require a concerted effort from all parts of the business and close alignment with the overall strategy. Learn more about the strategies from some successful case studies in the Asia-Pacific region.
Understand more about the Awareness, Affordability and Access strategic framework to drive success for global pharma companies engaging with Asian Markets.
While progress has been made in India over the past decade from both public and private sector initiatives, significant challenges persist in providing quality healthcare on an equitable, accessible and affordable basis across all regions and communities, according to a new IMS Institute for Healthcare Informatics study. A 40-45 percent reduction in out-of-pocket expenditures for both outpatient and inpatient treatments can be attained through a holistic approach addressing four critical, interrelated dimensions of healthcare access. Those components are: physical accessibility and the location of healthcare facilities; availability and capacity of needed resources; quality and functionality of service required for patient treatment; and affordability of treatment relative to a patient’s income.
The study – Understanding Healthcare Access in India: What is the Current State? – is the most comprehensive assessment of healthcare access undertaken since 2004 and is based on an extensive survey of nearly 15,000 households covering all socio-economic groups in rural and urban areas across 12 states. Information was gathered on more than 30,000 healthcare system interactions, supplemented by interviews with over 1,000 doctors and experts.
The full report is available at http://www.theimsinstitute.org for downloading.
This presentation wil provide you the latest trends (up to March 2013) on both Global and Asia Pacific OTC markets.
This presentation is in English and Mandarine.
This document provides a global perspective on the evolving biosimilars landscape and market. It finds that after slow initial growth, the biosimilars market is poised for accelerated expansion between 2015-2020 as major biologics lose patent protection, US legislation establishes a regulatory pathway, and payers increase adoption to control costs. The market could reach $1.9-2.6 billion by 2015, up from $378 million currently, with the largest opportunities in oncology, diabetes, and rheumatoid arthritis. Key drivers include cost pressures on healthcare systems and the availability of lower-cost biosimilar alternatives to expensive biologic drugs. However, significant barriers remain due to varying regulations worldwide and resistance from biologics manufacturers.
The document summarizes the changing landscape of the top 10 pharmaceutical companies from 2002 to 2012. It notes that while the companies have remained largely the same, there has been some shuffling between positions. It also discusses how the companies have diversified their business models through mergers and acquisitions, but this has failed to increase their collective market share. The rise of Teva into the top 10 reflects a greater emphasis on generics. Overall, the top companies face challenges in innovating new blockbuster drugs and achieving growth.
The top 20 multinational pharmaceutical companies in Asia will see an average of $950 million in sales become at risk in the next 5 years due to the loss of exclusivity of their top brands. How can MNCs survive and thrive in this increasingly genericized era?
Government cost containment methods in Asia-Pacific markets are as diverse as the cultures represented in the region, so what lessons are the markets leveraging from cost containment experiences? And what, in the end, are pharmaceutical companies supposed to do about it?
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
The insights driving superior healthcare outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region, delivering fresh perspectives on how to navigate through the challenges and opportunities in Asia-Pacific pharmaceutical market.
1. The document discusses opportunities for France and China to collaborate on improving China's healthcare system to address the country's changing demographic and economic landscape.
2. It outlines four priority areas: developing more patient-centric hospitals and health information systems, caring for an aging population, preventing and managing chronic diseases, and fighting infectious diseases.
3. France is well-positioned to offer relevant experiences and innovative solutions in these areas through its healthcare expertise, long-standing relationship with China, and companies working in areas like hospital design, elderly care, disease prevention and treatment.
The hospital segment in India is becoming increasingly attractive for pharmaceutical companies due to its large size, fast growth rate, and investment opportunities. However, pharmaceutical companies will need to rethink their business strategies to succeed in this evolving market. Hospitals are exerting more control over physician prescriptions and purchasing decisions. Additionally, the relationship between physicians and hospitals is shifting, with hospitals gaining more influence. To effectively engage with the hospital segment, pharmaceutical companies will need to tailor their strategies, products, targeting, and metrics to the unique dynamics of each hospital type.
The document provides insights into OTC market trends in the APAC region. It finds that growth in APAC comes from both innovation in new products and base sales growth, while the global market still relies heavily on price increases. Among key categories in APAC, pain relief is driving growth above the regional average, while categories like cough/cold struggle. The report also notes that just 4 of the top 10 OTC corporations in APAC are multinational companies, and only Takeda grows faster than the overall APAC market.
This document summarizes key trends in real-world evidence (RWE) research, with a focus on diabetes. It discusses how new mixed methods and analytic innovations are providing deeper insights into differential treatment responses in diabetes patient subgroups. It also describes emerging RWE strategies like disease-centric frameworks and increased commercial collaboration. Finally, it highlights advances in predictive modeling, leveraging Scandinavian data sources, and using RWE to evaluate disease burden and non-adherence impacts.
The insights driving superior healthcare
outcomes in Asia Pacific.
Asia-Pacific Insight Magazine brings together IMS Health experts from across the region to engage in conversations about the forces that are shaping healthcare in Asia - and the strategies necessary to surge ahead of the competition
Growing Pains. China new's realities and the necessity of an informed strateg...QuintilesIMS Asia Pacific
China is a rapidly evolving healthcare market. However companies that take too macroscopic approach to projecting growth, disregarding the more granular trends across drug categories, risk facing a gap between assumed and actual portfolio growth. To address this gap, companies have a variety of options, ranging across levels of difficulty and the degree of transformation necessary.
Download the paper to learn more.
To succeed in this dynamic healthcare industry, price-volume strategies require a concerted effort from all parts of the business and close alignment with the overall strategy. Learn more about the strategies from some successful case studies in the Asia-Pacific region.
Understand more about the Awareness, Affordability and Access strategic framework to drive success for global pharma companies engaging with Asian Markets.
While progress has been made in India over the past decade from both public and private sector initiatives, significant challenges persist in providing quality healthcare on an equitable, accessible and affordable basis across all regions and communities, according to a new IMS Institute for Healthcare Informatics study. A 40-45 percent reduction in out-of-pocket expenditures for both outpatient and inpatient treatments can be attained through a holistic approach addressing four critical, interrelated dimensions of healthcare access. Those components are: physical accessibility and the location of healthcare facilities; availability and capacity of needed resources; quality and functionality of service required for patient treatment; and affordability of treatment relative to a patient’s income.
The study – Understanding Healthcare Access in India: What is the Current State? – is the most comprehensive assessment of healthcare access undertaken since 2004 and is based on an extensive survey of nearly 15,000 households covering all socio-economic groups in rural and urban areas across 12 states. Information was gathered on more than 30,000 healthcare system interactions, supplemented by interviews with over 1,000 doctors and experts.
The full report is available at http://www.theimsinstitute.org for downloading.
This presentation wil provide you the latest trends (up to March 2013) on both Global and Asia Pacific OTC markets.
This presentation is in English and Mandarine.
This document provides a global perspective on the evolving biosimilars landscape and market. It finds that after slow initial growth, the biosimilars market is poised for accelerated expansion between 2015-2020 as major biologics lose patent protection, US legislation establishes a regulatory pathway, and payers increase adoption to control costs. The market could reach $1.9-2.6 billion by 2015, up from $378 million currently, with the largest opportunities in oncology, diabetes, and rheumatoid arthritis. Key drivers include cost pressures on healthcare systems and the availability of lower-cost biosimilar alternatives to expensive biologic drugs. However, significant barriers remain due to varying regulations worldwide and resistance from biologics manufacturers.
The document summarizes the changing landscape of the top 10 pharmaceutical companies from 2002 to 2012. It notes that while the companies have remained largely the same, there has been some shuffling between positions. It also discusses how the companies have diversified their business models through mergers and acquisitions, but this has failed to increase their collective market share. The rise of Teva into the top 10 reflects a greater emphasis on generics. Overall, the top companies face challenges in innovating new blockbuster drugs and achieving growth.
The top 20 multinational pharmaceutical companies in Asia will see an average of $950 million in sales become at risk in the next 5 years due to the loss of exclusivity of their top brands. How can MNCs survive and thrive in this increasingly genericized era?
Government cost containment methods in Asia-Pacific markets are as diverse as the cultures represented in the region, so what lessons are the markets leveraging from cost containment experiences? And what, in the end, are pharmaceutical companies supposed to do about it?
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
1. 1
Leveraging China’s Healthcare Reform
An audio interview with Mandy Chui, Practice Leader, PMA
AUDIO INTERVIEW!
Turn on your speakers.
2. Leveraging China’s Healthcare Reform
IMS Expert: Mandy Chui
Length: ~14:30
Mandy Chui
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
3. 3
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Mandy, this is a challenge of incredible proportions. Could
you help me put it into perspective by giving me some
background on Chinese healthcare leading up to reform?
Mandy Chui (MC): Yeah sure, during the last 20 years of the
economic development in China, in fact the healthcare system
has not been able to develop as fast as the growth in the
economy, so a lot of the hospitals there are overcrowded and
the government has reduced its funding into the whole system,
so that many hospitals have to become more profit-driven, and
many of the facilities are also inaccessible to the general public.
4. 4
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
So the reforms have really been designed to fix problems
created by the pre-existing system?
MC: In one way this is true. China has been growing, really fast
and also the population has been aging, a lot of the disease
patterns are changing as well. And there is also rapid
urbanization because a lot of people are moving from the rural
areas and working in the cities. And with the lifestyle changes, a
lot of the chronic diseases have also become more prominent
such as diabetes or hypertension. So the government also
needs to have the ability to treat patient populations affected by
these diseases, which are becoming more prominent, so they
have to set up an infrastructure that will be fitting to the
changes to the demographics and epidemiology of China.
Know more on IMS Health, click here
5. 5
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Now I understand that $125 billion will be invested in this
over a period of 3 years. How exactly is this money going
to be spent?
MC: I would say close to 50% will be spent on providing the
medical insurance coverage for the general public because the
aim is to have everyone covered under different schemes by
2020 and with about 90% covered by 2011.
Know more on IMS Health, click here
6. 6
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
MC: The second part is regarding the healthcare delivery
provision, so around maybe close to 47% of the money will be
spent to build up the infrastructure, especially around the
primary healthcare facilities such as the urban community
health centers, the village clinics, the township centers, and also
the county hospitals.
And the last bit is really to try to strengthen the public health
care services, such as prevention measures and reporting of
infectious disease and education of people and vaccination, etc.
Know more on IMS Health, click here
7. 7
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Now I understand there’s another very important element
in the form of an Essential Drug List, or EDL. Could you
tell us a little bit more about that?
MC: There are certain drugs, about 200 western medicines, the
government is going to have more compulsory usage or at least
encourage those primary care institutions to use these drugs for
their daily prescriptions. So these drugs are also going to be
more frequently prescribed.
Know more on IMS Health, click here
8. 8
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Will the EDL contain both traditional Chinese medicines
and Western medicines?
MC: Yes they do in the EDL altogether there are about 300 or so
drugs and 200 something of them are Western medicine and
about 102 are traditional Chinese medicines, so basically one
third, two thirds in terms of the Chinese medicine versus the
Western medicine.
Know more on IMS Health, click here
9. 9
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
And who are the key players in terms of Western
medicines?
MC: The key players are, in fact, mostly the generic local
companies but the multinational companies, they do have a
couple of drugs also included in the essential drugs list. These
companies, for example, are Astra Zeneca, Pfizer, Novartis, and
GSK.
Know more on IMS Health, click here
10. 10
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
So the government will be controlling the products
prescribed. Will the government be controlling the cost of
EDL products as well?
MC: Yes, certainly the government is going to set a ceiling price
for these EDL drugs because they want these drugs to be more
affordable to the general public. So in fact they have already
issued the first ceiling price of this essential drug list at the end
of October or November time.
Know more on IMS Health, click here
11. 11
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
And how exactly do they go about setting these prices?
MC: They are just, of course, they will benchmark the different
drugs looking at what is available in the market place and then
try to reference like a basket of drugs and set a reference price.
And basically what we have seen is that they are looking at the
different kinds of generics, not necessarily the cheapest, but
generally or certainly lower than, for example, some of the
drugs that are already off-patent and sharing the same
molecule so we have seen different examples.
Know more on IMS Health, click here
12. 12
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
What about producers of high-cost drugs? Where does this
leave them?
MC: For high-cost drugs, that typically are a more innovative
treatment option, there is a separate list called a national drug
reimbursement list, so most of the high price or newer
generation of drugs will be included in this national
reimbursement list. But for these innovative drugs, generally it
will not be fully reimbursable. It will be having different degrees
of copayment from the patients and, as you know, for China,
there is a lot of variation by the different provinces depending
on the funding of each province. So the list of drugs also has
some variations by the provinces.
Know more on IMS Health, click here
13. 13
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
So the EDL may be quite a double-edged sword for
pharmaceuticals companies. On the one hand,
manufacturers can expand their coverage across the
whole of China. But on the other hand, there’s significant
downward pressure on pricing.
MC: Yeah, this is true. At IMS Health, what we have observed is
that the government is setting a ceiling price for the EDL so
many of the companies if they have a drug that has already
gone off patent, they will have to be benchmarked against
generic drugs and the price will be much lower so that's why
that it will be a lot of pressure to lower price if they want to win
in the tender.
Know more on IMS Health, click here
14. 14
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
MC: But of course, on the other hand, there will be significant
benefit in terms of volume increase to cover this large
population. So the companies, they do need to weigh the
benefits and the risks of playing in this EDL sector.
Are all companies facing the same sorts of risks and
benefits? I mean, will individual companies need to
implement very different strategies, or will they all be
more or less the same, except in terms of scale?
Know more on IMS Health, click here
15. 15
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
MC: At IMS Health, we frequently find in mature and emerging
markets that companies need help to develop their individual
strategies. It’s not just a matter of scale. It also depends on
the company’s strategic intent and product portfolio and
especially their near-term pipeline. If they want to grow the top
line aggressively and want to become a top 5 player in the
marketplace they definitely have to consider playing in both the
premium segment and the mass segment. But for certain
companies they want to become more like a niche innovation
player or a focused therapeutic leader. Then they could choose
to just play in just one sector of the market. They want to
become like a specialized drug provider so they want to play
more in the acute conditions or more specialized conditions, and
the other way, they could just choose to play in the OTC sector.
Know more on IMS Health, click here
16. 16
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
And how do you see the reforms impacting OTC sales?
MC: The reforms are certainly having impact on the OTC
products because a lot of the products now are becoming
available as EDL drugs and the government is going to pay for it
and so it is fully reimbursable. The price is also lower because
the government promises to have zero mark-up for these drugs.
So a lot of the patients will be more incentivized to get these
drugs from the healthcare facilities rather than from a retail
pharmacy to get the drugs so we foresee there will be a lot of
shift for these kind of drugs from the retail pharmacy back to
the hospital setting so that's a minus point for the OTC area.
But in the longer run as the consumers are getting richer and
they also demand for more convenience and we will see OTC
drugs being a very bright spot in the longer run.
Know more on IMS Health, click here
17. 17
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
With so many changes in the market place, how do
companies prepare themselves to succeed?
MC: At IMS Health, we have observed that there are many
different companies that are at a different stage of their
planning. You know some companies are already looking at
what are the best strategies to cope with these changes. There
are companies that still wait and see, to fully understand what
the government healthcare reforms will mean to them. They are
in the process of also doing their planning and changing their
way of addressing the market because they are still very used
to this premium segment of just increasing the sales force, but
their cost structure and their capabilities are not very fit to this
mass segment and to compete with the local companies.
Know more on IMS Health, click here
18. 18
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
But entering the Chinese market would actually entail a
huge increase in the sales force, wouldn’t it?
MC: Well, of course sales reps are always a very important and
critical part of the pharmaceutical business in China. But now
with the opening up of this new segment there are different
stakeholders and the way of purchasing is going to be different.
There will be more of an essential purchasing system and you
need to develop some kind of engagement platform with each
province in order to influence them or the whole decision-
making process. So it will be extremely important to have a key
account management team to undertake this kind of work.
Know more on IMS Health, click here
19. 19
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
So what kind of strategic options are there for big pharma?
MC: At IMS Health, we have been helping clients develop
strategies in China and many other emerging markets. Many of
the pharmaceutical companies are looking at different options
and they are also looking at other markets where they could
learn the experience from and we see this for the big pharma,
they have options to form strategic alliances with the local
companies.
Know more on IMS Health, click here
20. 20
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
MC: At the moment in time, local companies are getting
stronger and stronger and they are also interested in the
overseas market. They are very interested to look at
cooperation opportunities with multinational companies; they
are gearing up themselves to become GMP-compliant or to get
approval from the FDA, and to be able to supply their finished
products as OEM suppliers to the big pharma, so they’re very
interested to be a very integral part of big pharma’s global
platform.
At the same time, the MNCs, if they work together with the local
companies, they can gain access to the mass population and the
distribution network from the local companies. So that will be a
very great opportunity for them to work together.
Know more on IMS Health, click here
21. 21
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
So there are advantages by forging relationships with local
companies. Are there other parties worth talking to?
MC: In China now, with the opening up of the rural areas with
the community health centers, the government is also looking at
different ways to supply the drugs and make them available to
the general public. And if the companies can work together with
some of the NGOs or other organizations to make drugs more
affordable and available to these people, the government will
certainly welcome these different initiatives.
Know more on IMS Health, click here
22. 22
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
But to what extent can they welcome new initiatives,
though? I mean, aren’t the mechanisms that dictate the
supply of drugs on the EDL set in stone?
MC: The government, they formed just a guiding principle
essentially around these different drug lists or how these drugs
have to be procured or supplied. But each individual local
government they do say exactly how this has to be
implemented. So companies, in fact, they could influence some
of the different mechanisms or policies of how it is implemented
and it is very important for them to engage with the local
stakeholders to influence the decisions later on.
Know more on IMS Health, click here
23. 23
To download an MP3 of this interview, click here.
To download the PDF transcript, click here.
Questions? Comments? Fill out the form at the end of this presentation.
Well, I’m afraid we’re almost out of time here, Mandy.
Thank you so much for sharing your insights into China’s
healthcare reform. It’s a very exciting time for the health
industry. And even more exciting for the people of China,
of course.
MC: Thank you very much, Andrew. It’s also a pleasure for me
to talk to you as well. And at IMS Health, we continue to consult
with our clients to improve their commercial and growth
strategies in mature and emerging markets such as China.
Know more on IMS Health, click here
24. 24
Thank you for listening!
• To download an MP3 of this interview, click here.
• To download the PDF transcript, click here.
• Questions? Comments?
− Fill out the form at the bottom of this slide, or
− Visit www.imshealth.com or email info.sg@sg.imshealth.com.